Published in
Royal Society of Chemistry, Biomaterials Science, 22(8), p. 6246-6260, 2020
DOI: 10.1039/d0bm01013h
Links
Tools
Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model
Journal article published in 2020 by
M. J. Rodrigo 
,
M. J. Cardiel ,
J. M. Fraile ,
S. Mendez-Martinez ,
T. Martinez-Rincon,
M. Subias ,
V. Polo,
J. Ruberte,
T. Ramirez,
E. Vispe,
C. Luna,
J. A. Mayoral,
E. Garcia-Martin
,
M. J. Cardiel ,
J. M. Fraile ,
S. Mendez-Martinez ,
T. Martinez-Rincon,
M. Subias ,
V. Polo,
J. Ruberte,
T. Ramirez,
E. Vispe,
C. Luna,
J. A. Mayoral,
E. Garcia-Martin
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Brimonidine-LAPONITE® formulation is a potential intravitreal formulation for glaucoma treatment. It exhibits an early ocular hypotensive effect and functional and structural neuroretinal protection over 24 weeks of follow-up, after single injection.